Nomura T
Central Institute for Experimental Animals, Kawasaki, Japan.
Lab Anim Sci. 1997 Apr;47(2):113-7.
Since transgenic (Tg) mice were first produced in 1980, the technology to produce genetically engineered animals, such as Tg and knock-out mice, has advanced exponentially. These animals have contributed greatly to basic research at the molecular level and have proven to be powerful tools for elucidating complex biological processes. The effort that is required to develop and establish genetically engineered animals as models for human diseases or toxicologic studies is not always appreciated by researchers and laboratory animal scientists. Genetically engineered animals remain only candidates of defined animal models until they are developed for practical use, in accordance with their objectives, through cooperation between the researchers performing the experiments and laboratory animal scientists. The practical development of these animals consists of three steps: establishment as standardized laboratory animals through the setting of quality standards and the establishment of a production and supply system; establishment as defined animal models through confirmation of the usefulness and limitations of the animal in the purpose of use; and establishment of an in vivo experimentation system (an animal experimentation system), using the defined animal models. This report serves as an introduction to those that follow and describes our concept of how best to establish genetically engineered animals as valid animal models. The development of Tg mice carrying the poliovirus receptor gene (PVR) will be used as an example. The TgPVR mice were produced by the introduction of the human poliovirus receptor gene into the mouse genome, mainly to study the molecular mechanisms of pathogenesis of the virus. The value of these mice is that they mimic human and nonhuman primate susceptibility to poliovirus infection and thus serve as a model for the study of the disease and for the assessment of poliovirus vaccines. They are being touted as a replacement for nonhuman primates in the neurovirulence testing of oral poliovirus vaccine.
自1980年首次培育出转基因(Tg)小鼠以来,生产基因工程动物(如Tg小鼠和基因敲除小鼠)的技术呈指数级发展。这些动物为分子水平的基础研究做出了巨大贡献,并已被证明是阐明复杂生物过程的有力工具。研究人员和实验动物科学家并不总是充分认识到将基因工程动物开发并确立为人类疾病模型或毒理学研究模型所需付出的努力。在根据实验研究人员与实验动物科学家之间的合作,按照其目标将基因工程动物开发用于实际用途之前,它们仍然只是特定动物模型的候选对象。这些动物的实际开发包括三个步骤:通过设定质量标准和建立生产与供应系统,将其确立为标准化实验动物;通过确认动物在预期用途中的有效性和局限性,将其确立为特定动物模型;以及使用特定动物模型建立体内实验系统(动物实验系统)。本报告作为后续内容的引言,描述了我们关于如何最好地将基因工程动物确立为有效动物模型的理念。将以携带脊髓灰质炎病毒受体基因(PVR)的Tg小鼠的培育为例进行阐述。TgPVR小鼠是通过将人脊髓灰质炎病毒受体基因导入小鼠基因组而培育出来的,主要用于研究该病毒发病机制的分子机制。这些小鼠的价值在于它们模拟了人类和非人类灵长类动物对脊髓灰质炎病毒感染的易感性,因此可作为研究该疾病和评估脊髓灰质炎病毒疫苗的模型。它们被吹捧为在口服脊髓灰质炎病毒疫苗神经毒力测试中替代非人类灵长类动物的对象。